Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 September 2020 | Story Andre Damons | Photo Supplied
Dr Satyajit Tripathy
Dr Satyajit Tripathy, a postdoctoral fellow from the Department of Pharmacology and Physiology, won the medal for the best oral performance at a UNESCO/UNITWIN network web seminar attended by more than 300 people from various institutions around the world.

A postdoctoral fellow in Pharmacology at the University of the Free State (UFS) was awarded a medal for the best oral e-poster presentation (Postdoctoral Fellow category) at a UNESCO/UNITWIN Network web seminar.

The two-day webinar with the theme Current concepts of Environmental Pollution by Electromagnetic field and Coronavirus was held in early August and was attended by more than 300 delegates from approximately 30 institutions from different countries.

Dr Satyajit Tripathy from the Department of Pharmacology won the medal for his outstanding research presentation on Employment of old options to control novel Coronavirus: Pros and Cons (authors: Barsha Dassarma, Satyajit Tripathy, MG Matsabisa). His presentations looked at immunotherapeutic techniques, such as the convalescent plasma (CP) therapy and possible diverse modes of action of the antimalarial drug hydroxychloroquine (HCQ) against COVID-19 infection.

The award will serve as motivation

He was excited to hear that he had won the award, says Dr Tripathy.

“I never thought I would win, but I tried my best. On the topic of possible modes of action of HCQ against the viral infection, we have published in the ‘International Journal of Antimicrobial Agents’ (S Tripathy, B Dassarma, H Chabalala, S Roy, and MG Matsabisa / International Journal of Antimicrobial Agents 56 (2020) 106028). All the authors are grateful to Prof Glen Taylor, Research Director at the UFS, and the UFS Department of Pharmacology, for giving us the opportunity,” says Dr Tripathy. 
According to him, receiving this award is a validation and boost to his confidence. “I am thankful to Prof Motlalepula Matsabisa (supervisor) and Dr Barsha Dassarma (my wife), who are also contributing actively to this project. Moreover, the award is a symbol of respect for my work and the acceptance of a greater responsibility to keep the UFS flag flying high.”
Dr Tripathy goes further to say that it will motivate him to work on HCQ or nano-HCQ delivery research on Coronaviruses. In his doctoral study, it has been found that chitosan-based nanochloroquine delivery increases antimalarial efficacy against rodent parasites. Against the Coronavirus, this type of approach might work to reduce the dose and increase the efficacy of HCQ, explains Dr Tripathy. 

Immediate saviour from the pandemic

In his presentation, Dr Tripathy argues that while the world is finding expedited approvals for the development of vaccines that are time-dependent, preventative, and possibly not a cure, physicians are considering the convalescent plasma (CP) therapy as an immediate saviour, and the antimalarial drug hydroxychloroquine (HCQ) as therapeutic options against COVID-19 infection, after assessing results from larger prospective, randomised, dose-determining controlled clinical trials. 
He concludes that, “Overall, in this situation of unavailability of specific medication, the CP therapy and HCQ treatment might act as an immediate saviour for society from the pandemic.”

News Archive

Shimlas have a bunch of fighters for a tough week, says Scholtz
2016-03-18


Scrumhalf Zee Mkhabela is one of the senior Shimla players who will have to help his team play three Varsity Cup matches within a week. Photo: Christaan Kotzé/SASPA

Luckily, he has a bunch of fighters in his rugby group to take on the week ahead, which is almost like a USSA rugby week with a lot of matches in a row.

This is what Hendro Scholtz, the Shimla coach, had to say about the upcoming Varsity Cup week, with his team playing three games within a week. His team will play against the University of Johannesburg (UJ) on 21 March 2016, after which they will face Maties in Cape Town on 24 March 2016, and then take on Pukke in the Mother City on 28 March 2016.

The schedule for the Varsity Cup series had to be adapted due to the recent unrest on campuses across South Africa.

According to Scholtz, the versatility of his players and the attitude of the University of the Free State (UFS) rugby team counts in their favour for the week that lies ahead. Several of the Shimla players can play in more than one position.

The Shimlas will travel with a group of 29 players, and will, after their match in the City of Gold, fly directly to Cape Town for their other two league matches.

“We will take six extra players (other than the 23-man squad) with us,” Scholtz said.

“One should select a group for this week that can fight, hang in there, and are able to play another match or two. It is like a USSA week where you need fighters.”

Prop Chase Morison, who was given a red card against the Central University of Technology in Johannesburg on 14 March 2016, wasn't sighted, and is available to play again. The Shimlas are still unbeaten after winning 10-9 against CUT in the FNB Stadium. Flyhalf Pieter-Steyn de Wet, who missed the game against CUT due to an injury, will be able to play against UJ.

The Kovsie Young Guns and Vishuis, the residence representative for the UFS, will also play a couple of matches in the coming week.

Fixtures:

Shimlas: 21 March: Shimlas v UJ (FNB Stadium); 24 March: Maties v Shimlas (Cape Town Stadium); 28 March: Puk v Shimlas (Cape Town Stadium).

Kovsie Young Guns: 19 March: Kovsie Young Guns v UJ (Rand Stadium); 24 March: Puk v Kovsie Young Guns (Rand Stadium).

Vishuis: 24 March: Vishuis tv Harlequins (NMMU, Rand Stadium); 26 March: Mopanie tv Vishuis (Tuks, (Wanderers Rugby Club); 28 March: Oppierif v Vishuis (UJ, FNB Stadium).

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept